Abstract submission
Abstract submission for EASL Congress 2025 is now closed.
Notification of abstract acceptance will be sent by 25 February 2025. All presenters of accepted abstracts will receive a code that will allow them to register with the early fees.
The late-breaker abstract submission period will be open from 26 February to 10 March 2025.
Submission timeline
*All presenters of accepted abstracts will receive a code that will allow them to register with the early fees.
Why submit?
Be part of a leading event
The EASL Congress is renowned as the largest and most influential hepatology congress globally. By submitting your abstract or case, you become an essential contributor to this exceptional event.
Share your insights
Your research, findings, and expertise can make a significant impact on the field. Abstract or case submission is your avenue to share your insights with a diverse audience of hepatology professionals, researchers, and experts.
Shape the conversation
By presenting your work, you have the opportunity to shape the conversations and discussions that will drive the future of hepatology. Your can ignite new ideas and avenues of exploration.
Engage with experts
EASL provides you with the platform to engage with leading experts, peers, and thought leaders in the field. The congress facilitates meaningful interactions that will enrich your understanding and network.
Recognition and awards
Outstanding contributions deserve recognition. Submitting your research could lead to awards and accolades, acknowledging the value and impact of your work.
Requirements and guidelines
Please note that figures, tables or images are no longer allowed.
Please be informed that the regular abstract submission (1 October-3 December 2024) will be followed by a late breaker submission from 26 February to 10 March 2025.
Late-breaker abstracts allow researchers to present their most recent and significant findings. They are intended to highlight groundbreaking research that was not completed in time for the initial deadline (regular submissions).
· They present the latest, up-to-date research findings that have become available after the regular submission deadline.
· The research is considered highly significant, with the potential to impact the field substantially.
· Clinical studies should be prospective in design; submission of retrospective clinical studies is strongly discouraged.
· Phase 1 trials will be considered only in poster format.
· Laboratory-based studies are not typically considered appropriate as late breakers.
Due to their importance, late-breaker abstracts are subject to a rigorous review process and are more competitive than regular abstracts. The acceptance rate is lower, and only the most compelling submissions are selected.
Before submitting a late breaker abstract, please make sure it fits those criteria.
For any questions about abstract submissions, please contact abstracts.easlcongress@easloffice.eu
Steatotic liver disease (SLD) is the new overarching term with metabolic dysfunction-associated liver disease (MASLD) replacing nonalcoholic fatty liver disease (NAFLD).
To summarise:
- Steatotic liver disease (SLD) is the overarching term to encompass the various aetiologies of steatosis.
- Nonalcoholic fatty liver disease (NAFLD) will now be metabolic dysfunction-associated steatotic liver disease (MASLD). MASLD encompasses patients who have hepatic steatosis and have at least one of five cardiometabolic risk factors.
- A new category, outside pure MASLD, termed MetALD (pronunciation: Met A-L-D) was introduced to describe those with MASLD who consume greater amounts of alcohol per week (140 g/week and 210 g/week for females and males respectively).
- Metabolic dysfunction-associated steatohepatitis (MASH) is the replacement term for NASH.
- Those with no metabolic parameters and no known cause have cryptogenic SLD.
When submitting your abstract, always use the new nomenclature as long as feasible.
If the outdated terminology is used in reference to an old or ongoing trial or in reference to a publication etc., this would be an exception.
Detailed information about the nomenclature consensus process is available in the Journal of Hepatology.
EASL recommends the use of the terms below instead of the term “alcoholic” to end the stigmatizing language in alcohol and liver disease.
| Prior term | Recommended term | Abbreviation |
| Alcoholism | Alcohol use disorder | AUD |
| Alcoholic | Person with alcohol use disorder | |
| Alcoholic hepatitis | Alcohol-associated hepatitis or alcohol-related hepatitis | AH |
| Alcoholic liver disease | Alcohol-associated liver disease or Alcohol-related liver disease | ALD |
| Alcoholic cirrhosis | Alcohol-associated cirrhosis or Alcohol-related cirrhosis | AC |
We encourage you to adjust your case submission accordingly where appropriate. Thank you!
Abstract submitters from Ukraine and low-income economies* will be exempted from the EUR 50 required to submit their abstract(s). If you are from one of these countries, you can submit your abstract cost-free.
*Please consult the World Bank classification to check if your country belongs to this category.
Abstract topics
The Scientific Committee is looking forward to receiving your abstracts on these major topics:
Basic Science, Cirrhosis & Complications, General Hepatology, Immune-mediated & Cholestatic Diseases, Liver Tumours, Metabolism, Alcohol & Toxicity, Viral Hepatitis, Public Health.
- Cirrhosis and its complications: ACLF and Critical illness
- Cirrhosis and its complications: Experimental and pathophysiology
- Cirrhosis and its complications: Other clinical complications except ACLF and critical illness
- Cirrhosis and its complications: Portal Hypertension
- Fibrosis / Stellate cell biology
- Gut microbiota and liver disease / Liver-organ crosstalk
- Hepatocyte biology
Liver development and regeneration
Liver immunology
Liver transplantation and hepatobiliary surgery
- Non-invasive assesment of liver disease except MASLD
- Rare liver diseases (including paediatric and genetic)
- Immune-mediated and cholestatic disease: Clinical aspects
- Immune-mediated and cholestatic: Experimental and pathophysiology
Liver tumours: Clinical aspects except therapy
Liver tumours: Experimental and pathophysiology
Liver tumours: Therapy
- Acute liver failure and drug induced liver injury
- Alcohol-related liver disease and MetALD
MASLD: Clinical aspects except therapy
MASLD: Diagnostics and non-invasive assessment
MASLD: Experimental and pathophysiology
MASLD: Therapy
Viral Hepatitis: Experimental and pathophysiology
Viral hepatitis A/E: Clinical aspects
Viral hepatitis B and D: Clinical aspects
Viral Hepatitis B and D: Current therapies
Viral Hepatitis B and D: New therapies, unapproved therapies or strategies
Viral Hepatitis C: Clinical aspects including follow up after SVR
Viral hepatitis C: Therapy and resistance
Public Health: Except viral hepatitis
Public Health: Viral hepatitis
Nurses and Allied Health Professionals
Abstract submission rules for EASL Congress 2025
I confirm that I have disclosed the following:
1. For each author, any relevant financial relationship with the provider of commercial products or services discussed in their educational presentation or that have directly supported the CME activity through an educational grant to the sponsoring organisation(s).
2. If the product, that is discussed in the abstract is not labelled for the use under discussion or that the product is still investigational.
3. I understand that I will disclose my conflict of interests in my presentation/poster and that my presentation complies with all relevant provisions of local legislation and guidelines governing communications between healthcare professionals, patients and the pharmaceutical industry.
The intent of disclosure is not to prevent a participant with financial or other relationships from making a presentation, but rather to provide participants with adequate information about the relationship(s).
EASL relies upon scientific committee members, session chairpersons, moderators, invited faculty and speakers participating in its CME programmes to provide educational information that is objective and free from bias. In this spirit, EASL follows those guidelines as set forth by the EACCME (Standards for Commercial Support, to disclose the existence of any relevant financial interest or other relationship the faculty member (spouse or partner) or provider has with the manufacturer of any commercial product discussed in an educational presentation.
Commitment from the submitter:
In submitting my abstract, I agree to abide by the conditions of EASL’s embargo policies. Should my abstract be accepted, I agree that I will refrain from sharing any of the findings or data of my abstract until such time as the embargo on my abstract lifts. If my abstract is selected for publication online or in print, before my embargo date, I commit to informing EASL immediately via email at abstracts.easlcongress@easloffice.eu.
Commitment from EASL:
In accepting your abstract submission, EASL commits to the following statement:
The content belongs to the author(s). However, if the abstract is accepted the submitter agrees, on behalf of all co-authors, to transfer and assign to EASL free of charge, on a non exclusive basis, for twenty years from the present submission the rights to edit, publish, reproduce, reformat, distribute in whole or in part the abstract and prepare all type of derivative works such as press releases and/or educational products, using all communication tools and means, now known or hereinafter developed, including any and all digital means and any and all supports or forms of media, now known or hereinafter developed, in particular all paper, analog, digital, numerical and electronic media, including Internet, Intranet and Extranet sites and social media. This includes use in indexes or search databases in print, electronic, or other media.
Author(s) retain the right, after presentation, to subsequently include the work in articles, books, or derivative works that he/she authors or edits, provided said use does not imply the endorsement of EASL.
The submitter signs for all co-authors. He/she accepts responsibility for the present rules for submission and presentation on behalf of all co-authors.
By submitting an abstract to the EASL Congress, you agree to abide by this embargo policy. The policy states that authors, presenters and/or their sponsors may not share data or key results from the abstract in any form (print, broadcast or online publication, media release or conference presentation) until this embargo is lifted. Authors, presenters and/or their sponsors may, however, publicise the fact that their abstract has been selected for inclusion in the congress programme before the abstract is officially released. In this context, they may publish the title of their abstract together with the names of the authors and institutions.
Embargos according to the category of submission
A detailed breakdown of the embargo policies for different types of abstracts is available below. All congress delegates, presenters, industry employees, sponsors, and media agree to respect this policy when submitting their abstracts or registering for the event.
- Accepted abstracts selected for the following sessions should not be disclosed before the start of EASL Congress 2025 at 8:00 CET on Wednesday, 7 May 2025 (the opening day of the congress). Authors will be informed during the abstract notification process if their abstract has been selected for one of these sessions.
- General Session I
- General Session II
- Late-breaker Session
2. EASL Congress Late-breaker abstracts (poster presentations only): Data from abstracts submitted during the late-breaker submission period and which have been selected for poster presentation may not be disclosed before the start of EASL Congress 2025 at 8:00 CET on Wednesday, 7 May 2025 (the opening day of the congress).
3. Accepted abstracts selected for the following sessions should not be disclosed before 8:00 CET on Wednesday, 23 April 2025 (i.e. two weeks before the start of the congress).
- Oral sessions (excluding General Session I, General Session II, Late-breaker Session, or pre-selected abstracts for potential inclusion in an EASL Congress press release)
- Poster sessions (excluding pre-selected abstracts for potential inclusion in an EASL Congress press release and late-breaker)
Note: All pre-recorded presentations may not be disclosed before the start time of their presentation in the official programme. Posters, ePosters and ePoster videos may not be disclosed before 8:00 CET on Wednesday, 7 May 2025 (the first day of the event).
Embargo breaks
Examples of breaking the embargo include publishing data from the abstract in a journal or via a public outlet before the abstract is presented at the congress. Violation of the embargo policy above will be taken seriously. Individuals and/or sponsors who violate it may face sanctions relating to current and future abstract submissions, presentations, and visibility at EASL events. The EASL Governing Board is at liberty to ban attendance and/or retract data.
If you find out that data from an abstract you submitted to EASL Congress 2025 is scheduled for publication prior to the lifting of the embargo, please inform the EASL Congress 2025 team immediately at abstracts.easlcongress@easloffice.eu.
Please direct any questions or concerns about the EASL Congress embargo policy for authors and presenters to the EASL Congress 2025 team at abstracts.easlcongress@easloffice.eu.
I confirm that the submitted abstract will include scientific/study results data (commercial content is not allowed) only. In the case that it is submitted by a non-academic company, the presenter must be part of the medical affairs or clinical development team.
Abstracts that have been presented in previous non-EASL International Gastroenterology/Hepatology Meetings are NOT accepted.
If this rule is not respected, the abstract will be rejected and will not be considered for EASL Congress 2025.
“If my abstract is accepted for presentation (oral or poster) at EASL Congress 2025, I agree to present my abstract at the congress. I declare that my abstract contains original research that has not been published or accepted for publication for another meeting or conference and/or in a print or online journal.”
I understand that EASL charges 50 EUR (excl. VAT) for each regular abstract submission (100 EUR for late-breaker abstracts).
This is a non-refundable fee, regardless of the abstract acceptance status.
I understand that even if EASL will do its best effort to accommodate withdrawal request(s) past the abstract submission deadline, complete withdrawal past the deadline cannot be guaranteed.
